LSPedia wants to update you on significant developments from the FDA that may impact your operations. On October 9, 2024, the FDA issued new guidance granting temporary exemptions from DSCSA Section 582(g) requirements for certain trading partners. This advisory provides an overview of these exemptions and how they might affect your operations.
Overview of the Exemption
The FDA's guidance extends temporary exemptions beyond the initial stabilization period ending November 27, 2024. This Exemption is aimed at trading partners who have initiated systems for the electronic, interoperable exchange of transaction information but are facing challenges with data quality and reliability.
Key Points of the Exemption
Impact on Your Business
This exemption allows your organization to continue operations without the immediate pressure of the original regulatory deadlines. It provides additional time to refine and improve your DSCSA operations, facilitating your trading partners' efforts to catch up with data connections.
Action Items
LSPedia advises all our customers to assess their current exemption status and ensure their processes are compliant:
Exemption Tracking with OneScan
OneScan can significantly help in assessing your own and your trading partners' eligibility status.
Thank you for your attention to this important matter. LSPedia looks forward to assisting you in making this transition as smooth as possible.